ticlopidine has been researched along with Fibrosis in 11 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using a mouse model of angiotensin II (Ang II) infusion (1,500 ng/[kg·min] for 7 days), we determined the role of platelet activation in Ang II infusion-induced cardiac inflammation and fibrosis using a P2Y12 receptor inhibitor, clopidogrel (50 mg/[kg·day])." | 7.79 | Inhibition of platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis. ( Cui, W; Du, J; Jia, LX; Li, TT; Liu, O; Qi, GM; Qi, YF; Yang, M; Zhang, WM, 2013) |
| "Warfarin treatment within 12 months achieved significantly higher rates of complete recanalization than aspirin or clopidogrel in patients with PVT (54." | 5.48 | Portal Vein Thrombosis in Patients With Cirrhosis Undergoing Elective Transjugular Intrahepatic Portosystemic Shunt: Risk Factors, Warfarin Efficacy, and Clinical Outcomes. ( Li, YH; Wu, HM; Xu, Y; Yang, J; Yang, LH; Yue-Meng, W, 2018) |
| "All ticagrelor treatments improved left ventricular ejection fraction, acute (69." | 5.42 | Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction. ( Birnbaum, GD; Birnbaum, Y; Nanhwan, MK; Nylander, S; Perez-Polo, JR; Ye, Y, 2015) |
| "Using a mouse model of angiotensin II (Ang II) infusion (1,500 ng/[kg·min] for 7 days), we determined the role of platelet activation in Ang II infusion-induced cardiac inflammation and fibrosis using a P2Y12 receptor inhibitor, clopidogrel (50 mg/[kg·day])." | 3.79 | Inhibition of platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis. ( Cui, W; Du, J; Jia, LX; Li, TT; Liu, O; Qi, GM; Qi, YF; Yang, M; Zhang, WM, 2013) |
| "Clopidogrel is a widely used anti-thrombotic for the prevention of stent thrombosis and cardiovascular events in patients with coronary atherosclerosis." | 3.75 | Clopidogrel attenuates atheroma formation and induces a stable plaque phenotype in apolipoprotein E knockout mice. ( Afek, A; George, J; Keren, G; Kogan, E; Maysel-Auslender, S; Mor, A; Regev, E; Rubinstein, A, 2009) |
| "Warfarin treatment within 12 months achieved significantly higher rates of complete recanalization than aspirin or clopidogrel in patients with PVT (54." | 1.48 | Portal Vein Thrombosis in Patients With Cirrhosis Undergoing Elective Transjugular Intrahepatic Portosystemic Shunt: Risk Factors, Warfarin Efficacy, and Clinical Outcomes. ( Li, YH; Wu, HM; Xu, Y; Yang, J; Yang, LH; Yue-Meng, W, 2018) |
| "24." | 1.43 | Relationship Between Platelet Reactivity and Culprit Lesion Morphology: An Assessment From the ADAPT-DES Intravascular Ultrasound Substudy. ( Brodie, BR; Duffy, PL; Inaba, S; Kirtane, AJ; Maehara, A; Mazzaferri, EL; Metzger, DC; Mintz, GS; Rinaldi, MJ; Shimizu, T; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B; Yun, KH, 2016) |
| "All ticagrelor treatments improved left ventricular ejection fraction, acute (69." | 1.42 | Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction. ( Birnbaum, GD; Birnbaum, Y; Nanhwan, MK; Nylander, S; Perez-Polo, JR; Ye, Y, 2015) |
| "Chronic myocardial ischemia was induced using a minimally invasive model in 16 landrace pigs." | 1.37 | Gene therapy with iNOS enhances regional contractility and reduces delayed contrast enhancement in a model of postischemic congestive heart failure. ( Abegunewardene, N; Gori, T; Horstick, G; Kreitner, KF; Lehr, HA; Münzel, T; Schmidt, KH; Schreiber, LM; Vosseler, M, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jia, LX | 1 |
| Qi, GM | 1 |
| Liu, O | 1 |
| Li, TT | 1 |
| Yang, M | 1 |
| Cui, W | 1 |
| Zhang, WM | 1 |
| Qi, YF | 1 |
| Du, J | 2 |
| Du, XJ | 1 |
| Kiriazis, H | 1 |
| Opie, LH | 1 |
| Lakshmanan, M | 1 |
| Ye, Y | 1 |
| Birnbaum, GD | 1 |
| Perez-Polo, JR | 1 |
| Nanhwan, MK | 1 |
| Nylander, S | 1 |
| Birnbaum, Y | 1 |
| Yun, KH | 1 |
| Mintz, GS | 1 |
| Witzenbichler, B | 1 |
| Inaba, S | 1 |
| Shimizu, T | 1 |
| Metzger, DC | 1 |
| Rinaldi, MJ | 1 |
| Mazzaferri, EL | 1 |
| Duffy, PL | 1 |
| Weisz, G | 1 |
| Stuckey, TD | 1 |
| Brodie, BR | 1 |
| Kirtane, AJ | 1 |
| Stone, GW | 1 |
| Maehara, A | 1 |
| Yue-Meng, W | 1 |
| Li, YH | 1 |
| Wu, HM | 1 |
| Yang, J | 1 |
| Yang, LH | 1 |
| Xu, Y | 1 |
| Afek, A | 1 |
| Kogan, E | 1 |
| Maysel-Auslender, S | 1 |
| Mor, A | 1 |
| Regev, E | 1 |
| Rubinstein, A | 1 |
| Keren, G | 1 |
| George, J | 1 |
| Abegunewardene, N | 1 |
| Schmidt, KH | 1 |
| Vosseler, M | 1 |
| Kreitner, KF | 1 |
| Schreiber, LM | 1 |
| Lehr, HA | 1 |
| Gori, T | 1 |
| Münzel, T | 1 |
| Horstick, G | 1 |
| Wang, J | 1 |
| Albertson, CM | 1 |
| Zheng, H | 1 |
| Fink, LM | 1 |
| Herbert, JM | 1 |
| Hauer-Jensen, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents[NCT00638794] | 8,575 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 other studies available for ticlopidine and Fibrosis
| Article | Year |
|---|---|
Inhibition of platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis.
Topics: Angiotensin II; Animals; Clopidogrel; Fibrosis; Hypertension; Interleukin-1beta; Male; Mice; Mice, I | 2013 |
Pro-inflammatory role of platelets in hypertension-mediated end-organ damage : Editorial to: "Inhibition of Platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis" by L.-X. Jia et al.
Topics: Animals; Clopidogrel; Fibrosis; Hypertension; Male; Myocarditis; Platelet Aggregation Inhibitors; Pu | 2013 |
Hypertension, platelets, and inflammatory responses.
Topics: Animals; Fibrosis; Hypertension; Male; Myocarditis; Platelet Aggregation Inhibitors; Purinergic P2Y | 2014 |
Answer to: "Histogram and vertical bar diagram: often misapprehended concept" by M. Lakshmanan.
Topics: Animals; Fibrosis; Hypertension; Male; Myocarditis; Platelet Aggregation Inhibitors; Purinergic P2Y | 2014 |
Histogram and vertical bar diagram: often misapprehended concept.
Topics: Animals; Fibrosis; Hypertension; Male; Myocarditis; Platelet Aggregation Inhibitors; Purinergic P2Y | 2014 |
Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction.
Topics: Adenosine; Administration, Oral; Animals; Apoptosis; Cardiotonic Agents; Clopidogrel; Disease Models | 2015 |
Relationship Between Platelet Reactivity and Culprit Lesion Morphology: An Assessment From the ADAPT-DES Intravascular Ultrasound Substudy.
Topics: Aged; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Vessels; Drug Resistan | 2016 |
Portal Vein Thrombosis in Patients With Cirrhosis Undergoing Elective Transjugular Intrahepatic Portosystemic Shunt: Risk Factors, Warfarin Efficacy, and Clinical Outcomes.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Elective Surgical Procedures; Female; Fibrosis | 2018 |
Clopidogrel attenuates atheroma formation and induces a stable plaque phenotype in apolipoprotein E knockout mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cell Proliferation; Cells, Cultured; Clopidogrel; Disea | 2009 |
Gene therapy with iNOS enhances regional contractility and reduces delayed contrast enhancement in a model of postischemic congestive heart failure.
Topics: Animals; Anticoagulants; Aspirin; Clopidogrel; Contrast Media; Coronary Angiography; Coronary Stenos | 2011 |
Short-term inhibition of ADP-induced platelet aggregation by clopidogrel ameliorates radiation-induced toxicity in rat small intestine.
Topics: Adenosine Diphosphate; Animals; Chemotaxis, Leukocyte; Clopidogrel; Collagen; Endothelium, Vascular; | 2002 |